Myriad Genetics, MYGN
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (LSE:0K3W) from Neutral to Overweight. As of March 4, 2025, the average one-year price target for ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
StockStory.org on MSN4d
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results